Join to View Full Profile
40 Duke Medicine CirDurham, NC 27710
Phone+1 919-684-8111
Dr. Kang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2007 - 2010
University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 2005 - 2007
St Luke's HospitalInternship, Internal Medicine, 2004 - 2005- The Second Military Medicine UnivClass of 1985
Certifications & Licensure
SC State Medical License 2010 - 2027
NC State Medical License 2007 - 2026
IA State Medical License 2005 - 2007
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant Start of enrollment: 2011 Dec 01
- Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma Start of enrollment: 2011 Aug 01
- Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation Start of enrollment: 2012 May 01
- Join now to see all
Publications & Presentations
PubMed
- Targeting STK17B kinase activates ferroptosis and suppresses drug resistance in multiple myeloma.Zhibo Yan, Zhannan Han, Yihui Wang, Maja Beus, Yu Zhang
Blood. 2025-09-12 - Optimized Monothiol Thioredoxin Derivative (ORP100S) Protects In Vitro and In Vivo from Radiation and Chemotoxicity Without Promoting Tumor Proliferation.Jian Wu, Xiaobei Wang, Parker Mathews, Shaima Jabbar, Min Zhang
Advanced Science. 2025-09-11 - Correction: High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.Dharshan Sivaraj, Wendi Bacon, Gwynn D Long, David A Rizzieri, Michael E Horwitz
Bone Marrow Transplantation. 2025-09-01
Abstracts/Posters
- Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...Yubin Kang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...Yubin Kang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
OncLive® Presents State of the Science Summit™ on Hematologic MalignanciesApril 25th, 2019
RedHill Biopharma Announces Presentation on YELIVA® (Opaganib) for Multiple Myeloma at EORTC-NCI-AACR SymposiumNovember 14th, 2018
Grant Support
- Thioredoxin derivatives for radiation mitigationDUKE UNIVERSITY2025–2030
- Role of SLAMF7 in Racial Disparities in MyelomaDUKE UNIVERSITY2023–2025
- Enhancing CAR T therapy in multiple myelomaDUKE UNIVERSITY2022–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
